/PRNewswire/ ILIAS Biologics Inc., a biotech company dedicated to developing a new treatment modality, engineered exosome therapeutics, announced today that.
Share this article
Share this article
DAEJEON, South Korea, Feb. 1, 2021 /PRNewswire/ ILIAS Biologics, Inc. announced that its latest research in collaboration with researchers at The University of Texas Medical Brand at Galveston (UTMB) is published in the journal
Science Advances(Link: https://advances.sciencemag.org/content/7/4/eabd3865). The study showed successful results in preventing preterm birth and improving the fetus viability with ILB-202, ILIAS s anti-inflammatory exosomes developed through its EXPLOR® platform technology.
This study result is the second proof of concept that suggests significant anti-inflammatory effects of the same exosome (ILB202) from ILIAS Biologics, Inc. In April 2020, the researchers at the Korea Advanced Institute of Science and Technology (KAIST) and the ILIAS team published the same exosome s substantial efficacy in the septic mouse model in
The results of a study by researchers at the University of Texas Medical Branch may pave the way for a new medicine delivery system that could reduce the incidence of pre-term labor and premature birth by allowing physicians to treat the 'fetus as the patient'.
E-Mail
GALVESTON, Texas - The results of a study by researchers at the University of Texas Medical Branch may pave the way for a new medicine delivery system that could reduce the incidence of pre-term labor and premature birth by allowing physicians to treat the fetus as the patient . The study has been published in
Science Advances.
It has long been suspected that pre-term labor is triggered by inflammation caused by a sick fetus. A new study by scientists at UTMB has proved the hypothesis by studying several important assumptions about the relationship between the health of a mother and her unborn child.